Skip to main content
Premium Trial:

Request an Annual Quote

BioCommerce Week s Index to the Diversified Molecular Biology Tools Companies: Sep 23, 2004

Invitrogen Advances 8 Percent on Index

Shares of Invitrogen closed up at $58.49 at market close on Tuesday, 9 percent over last week’s close, to lead gainers over the week on BioCommerce Week’s Index to the Diversified Biology Tools Companies. Overall, the index finished up for a third-straight week at $32.19 from $31.71 one week ago (see table).

The index is a weekly compliation of stock prices of molecular tools companies with multiple platform technologies or business units, executives dedicated to integrated biology efforts, or have made investments in the field. These companies may be the first to react to the demands of the emerging market developing to create a layer of interoperative technology that bridges the data silos of the ‘omics’ industries and provides a broader view of molecular biology processes.

Invitrogen’s rise comes after the company was added to the S&P MidCap 400 Index after the close of trading Monday. PerkinElmer led losers with a 3.6 percent fall, finishing at $18.30 from $18.71 last week.

— Mo Krochmal ([email protected])

File Attachments
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.